Get started
Author

Shuhao Ji

Observed names: Ji, Shuhao, S.-Q. Ji
ORCID: 0009-0006-9442-7399
Observed ORCID: 0009-0006-9442-7399
OpenAlex ID: A5055344816
LILRB4 on multiple myeloma cells promotes bone lesion by p-SHP2/NF-κB/RELT signal pathway
2024 · Hongying Wang, Lei Wang, et al. · Journal of Experimental & Clinical Cancer Research · 22
PDF
Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2023 · Yifan Liu, Hongying Wang, et al. · Cancer Research · 18
IGSF9 promotes tumor invasion and metastasis through GSK-3β/β-catenin mediated EMT in lung cancer
2024 · Huiwen Luan, Ting Wang, et al. · Neoplasia · 16
IGSF9-targeted therapy inhibits the progression of acute myeloid leukemia
2025 · Lijun Hui, Jing Xiao, et al. · Blood Advances · 5
PDF
LILRB4 specific overexpression in myeloid cells promotes tumor progression and immunosuppression in mouse models
2025 · Hongying Wang, Shuhao Ji, et al. · Biochemical and Biophysical Research Communications · 3
Supplementary Data from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2023 · Yifan Liu, Hongying Wang, et al. · 1
Figure S2 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
Figure S3 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
PDF
Figure S1 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
PDF
Figure S4 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
Figure S6 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
PDF
Figure S7 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
Figure S5 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
Figure S8 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
PDF
Supplementary Data from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
PDF
Figure S8 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Supplementary Data from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Figure S6 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Figure S7 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Figure S3 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Figure S4 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Figure S5 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Figure S2 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Figure S1 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Data from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Works count: 54
Citation count: 65
H-index: 4
I10-index: 3
Year
Topic
Type